Parotid gland cancer

Summary

Parotid gland cancer (MONDO:0004700) is a cancer and 3 clinical trials. Top therapeutic interventions include pembrolizumab. A subtype of parotid gland neoplasm — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Classification: Cancer
• Clinical trials: 3

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	parotid gland cancer
Mondo ID	MONDO:0004700
MeSH	D010307
DOID	DOID:9036
ICD-10-CM	C07
ICD-11	1640200163
NCIT	C3525
SNOMED CT	363379000
UMLS	C0747273
MedGen	152885
GARD	0027703
Anatomy (UBERON)	UBERON:0001831
Is cancer (heuristic)	yes

Also known as: cancer of parotid · cancer of parotid gland · cancer of the parotid · cancer of the parotid gland · malignant neoplasm of parotid · malignant neoplasm of parotid gland · malignant neoplasm of the parotid · malignant neoplasm of the parotid gland · malignant parotid gland neoplasm · malignant parotid gland tumor · malignant parotid gland tumour · malignant parotid neoplasm · malignant parotid tumor · malignant parotid tumour · malignant tumor of parotid · malignant tumor of parotid gland · malignant tumor of the parotid · malignant tumor of the parotid gland · malignant tumour of parotid · malignant tumour of parotid gland (+3 more)

Disease family

This is a subtype of parotid gland neoplasm. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › mouth disorder › salivary gland disorder › parotid disorder › parotid gland neoplasm › parotid gland cancer

Related subtypes (1): benign neoplasm of parotid gland

Subtypes (1): carcinoma of parotid gland

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

Drugs indicated or in trials for this disease

No drug has an approved disease-direct ChEMBL indication for this disease.

1 drug in clinical trials for this disease (phase 2–3, investigational): efficacy not established — a trial record, not an indication.

Drug	Highest phase
Pembrolizumab	Phase 2

Clinical trials & evidence

Clinical trials

Clinical trials: 3.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE2	2
PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT02628067	PHASE2	ACTIVE_NOT_RECRUITING	Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158)
NCT04870762	PHASE2	RECRUITING	Customized 3D Printed Oral Stents During Head and Neck Radiotherapy
NCT00405405	PHASE1	COMPLETED	Phase I of Biologics and Chemoradiation Therapy for Advanced Head and Neck Cancer

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
PEMBROLIZUMAB	4	1